BFRIW
MaterialsBiofrontera Inc - Warrants (27/10/2026)
Live · NASDAQ · May 9, Close
What's Moving BFRIW Today?
No stock-specific AI insight has been generated for BFRIW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.04
Fundamentals
Trading
BFRIW News
20 articles- Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026Yahoo Finance·May 8, 2026
- Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...Yahoo Finance·Mar 21, 2026
- Biofrontera Inc. Q4 2025 Earnings Call SummaryMoby·Mar 19, 2026
- Biofrontera (BFRI) Q4 2025 Earnings TranscriptMotley Fool·Mar 19, 2026
- Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateYahoo Finance·Mar 19, 2026
- Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDTYahoo Finance·Dec 2, 2025
- Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes FinancingYahoo Finance·Nov 7, 2025
- Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10MYahoo Finance·Nov 7, 2025
- Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025Yahoo Finance·Nov 6, 2025
- Biofrontera Inc. close purchase of all Ameluz, RhodoLED U.S. assetsYahoo Finance·Oct 24, 2025
- Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AGYahoo Finance·Oct 23, 2025
- Biofrontera Inc. (NASDAQ:BFRI): When Will It Breakeven?Yahoo Finance·Sep 28, 2025
- Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025Yahoo Finance·Sep 26, 2025
- Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication ProgramYahoo Finance·Sep 23, 2025
- Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and TrunkYahoo Finance·Sep 16, 2025
- Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne VulgarisYahoo Finance·Aug 25, 2025
- Biofrontera Inc (BFRI) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Operational ...Yahoo Finance·Aug 15, 2025
- Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business UpdateYahoo Finance·Aug 13, 2025
- Biofrontera Inc. Appoints George Jones as Chief Commercial OfficerYahoo Finance·Aug 11, 2025
- Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025Yahoo Finance·Aug 4, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.04
Fundamentals
Trading
About Biofrontera Inc - Warrants (27/10/2026)
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative dermatological therapies, with a particular focus on skin cancer treatments. Its flagship product, Ameluz, is a leading therapy for actinic keratosis, supported by a state-of-the-art photodynamic therapy system designed to maximize patient outcomes. Committed to expanding its product portfolio and market presence, Biofrontera is poised to address critical unmet needs in skin health while fostering strategic partnerships to enhance its growth trajectory. With an increasing global demand for effective skin cancer solutions, the company is strategically positioned for future growth and success in this vital healthcare sector.